Zelira wins Gov tax refund for cannabinoid research
Biopharma company Zelira Therapeutics has been awarded a $1.2 million cash refund under the Government’s R&D Tax Incentive Scheme, for use on its cannabis-based medical research into autism.
AuManufacturing
AuManufacturing
